Patient characteristics and distribution in subgroups
| Parameter . | No. . | Percentage of all patients* . | Median value ± SD . | Minimum . | Maximum . |
|---|---|---|---|---|---|
| Included patients | 909 | 100.0 | |||
| Age, y | 67 ± 4.9 | 61.0 | 87.0 | ||
| 61-65 | 364 | 40.0 | |||
| More than 65 | 545 | 60.0 | |||
| Sex | |||||
| Female | 440 | 48.4 | |||
| Male | 469 | 51.6 | |||
| ECOG | |||||
| 0 | 78 | 11.8 | |||
| 1 | 277 | 41.8 | |||
| 2 | 225 | 34.0 | |||
| 3 | 67 | 10.1 | |||
| 4 | 15 | 2.3 | |||
| Not done | 247 | ||||
| Less than or equal to 2 | 580 | 87.6 | |||
| More than 2 | 82 | 12.4 | |||
| WBC, /μL | 9.3 ± 54.5 | 0.2 | 465.9 | ||
| Less than or equal to 20 | 563 | 62.1 | |||
| More than 20 | 343 | 37.9 | |||
| Not done | 3 | ||||
| LDH, U/L | 379.5 ± 616.9 | 3.8 | 7096.2 | ||
| Less than or equal to 700 | 640 | 75.1 | |||
| More than 700 | 212 | 24.9 | |||
| Not done | 57 | ||||
| Disease status | |||||
| Disease status | 673 | 74.0 | |||
| Preexisting MDS | 204 | 22.4 | |||
| Treatment-associated | 32 | 3.5 | |||
| CD34 expression | 27 ± 29.7 | 0.0 | 99.0 | ||
| Less than or equal to 10% | 237 | 32.1 | |||
| More than 10% | 502 | 67.9 | |||
| Not done | 170 | ||||
| Karyotype | |||||
| Favorable risk | 38 | 4.2 | |||
| Intermediate risk | 689 | 75.8 | |||
| High risk* | 182 | 20.0 | |||
| FLT3-ITD mutation | |||||
| Positive | 145 | 20.7 | |||
| Negative | 556 | 79.3 | |||
| Not done | 208 | ||||
| NPM1 mutation | |||||
| Positive | 186 | 27.5 | |||
| Wild-type | 490 | 72.5 | |||
| Not done | 233 | ||||
| NPM1/FLT3 status | |||||
| NPM+/FLT3−ITD− | 106 | 16.0 | |||
| NPM+/FLT3−ITD+ | 78 | 11.8 | |||
| NPM−/FLT3−ITD+ | 65 | 9.8 | |||
| NPM−/FLT3−ITD− | 414 | 62.4 | |||
| Not done | 246 | ||||
| BM blasts day 15 | 15 ± 29.6 | 0.0 | 100.0 | ||
| Less than or equal to 10% | 263 | 46.3 | |||
| More than 10% | 305 | 53.7 | |||
| Not done | 341 |
| Parameter . | No. . | Percentage of all patients* . | Median value ± SD . | Minimum . | Maximum . |
|---|---|---|---|---|---|
| Included patients | 909 | 100.0 | |||
| Age, y | 67 ± 4.9 | 61.0 | 87.0 | ||
| 61-65 | 364 | 40.0 | |||
| More than 65 | 545 | 60.0 | |||
| Sex | |||||
| Female | 440 | 48.4 | |||
| Male | 469 | 51.6 | |||
| ECOG | |||||
| 0 | 78 | 11.8 | |||
| 1 | 277 | 41.8 | |||
| 2 | 225 | 34.0 | |||
| 3 | 67 | 10.1 | |||
| 4 | 15 | 2.3 | |||
| Not done | 247 | ||||
| Less than or equal to 2 | 580 | 87.6 | |||
| More than 2 | 82 | 12.4 | |||
| WBC, /μL | 9.3 ± 54.5 | 0.2 | 465.9 | ||
| Less than or equal to 20 | 563 | 62.1 | |||
| More than 20 | 343 | 37.9 | |||
| Not done | 3 | ||||
| LDH, U/L | 379.5 ± 616.9 | 3.8 | 7096.2 | ||
| Less than or equal to 700 | 640 | 75.1 | |||
| More than 700 | 212 | 24.9 | |||
| Not done | 57 | ||||
| Disease status | |||||
| Disease status | 673 | 74.0 | |||
| Preexisting MDS | 204 | 22.4 | |||
| Treatment-associated | 32 | 3.5 | |||
| CD34 expression | 27 ± 29.7 | 0.0 | 99.0 | ||
| Less than or equal to 10% | 237 | 32.1 | |||
| More than 10% | 502 | 67.9 | |||
| Not done | 170 | ||||
| Karyotype | |||||
| Favorable risk | 38 | 4.2 | |||
| Intermediate risk | 689 | 75.8 | |||
| High risk* | 182 | 20.0 | |||
| FLT3-ITD mutation | |||||
| Positive | 145 | 20.7 | |||
| Negative | 556 | 79.3 | |||
| Not done | 208 | ||||
| NPM1 mutation | |||||
| Positive | 186 | 27.5 | |||
| Wild-type | 490 | 72.5 | |||
| Not done | 233 | ||||
| NPM1/FLT3 status | |||||
| NPM+/FLT3−ITD− | 106 | 16.0 | |||
| NPM+/FLT3−ITD+ | 78 | 11.8 | |||
| NPM−/FLT3−ITD+ | 65 | 9.8 | |||
| NPM−/FLT3−ITD− | 414 | 62.4 | |||
| Not done | 246 | ||||
| BM blasts day 15 | 15 ± 29.6 | 0.0 | 100.0 | ||
| Less than or equal to 10% | 263 | 46.3 | |||
| More than 10% | 305 | 53.7 | |||
| Not done | 341 |
MDS indicates myelodysplastic syndrome.
All patients with results.